TPCW
PCVX icon

TD Private Client Wealth’s Vaxcyte PCVX Stock Holding History

TD Private Client Wealth’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-3
Closed -$174 – 1752
2026
Q1 		$174 Hold
3
– – ﹤0.01% 1586
2025
Q4 		$138 Buy
+3
New +$134 ﹤0.01% 1586
2025
Q2 		– Sell
-18
Closed -$680 – 1487
2025
Q1 		$680 Buy
+18
New +$1.44K ﹤0.01% 1323

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

TD Private Client Wealth's PCVX Position: Q2 2026 in Review

TD Private Client Wealth sold out of Vaxcyte (PCVX) in Q2 2026, closing a stake of 3 shares — an estimated $174 sold.

TD Private Client Wealth first reported a position in PCVX in Q1 2025 and held it in 3 quarters. The position peaked at $680 in Q1 2025. 331 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

  • TD Private Client Wealth reported no remaining Vaxcyte position as of Q2 2026 after selling out during the quarter.
  • TD Private Client Wealth sold 3 Vaxcyte shares in Q2 2026, an estimated $174.
  • TD Private Client Wealth first reported a position in Vaxcyte in Q1 2025 and held it in 3 quarters.
  • TD Private Client Wealth's Vaxcyte position peaked at $680 in Q1 2025.
  • 331 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on TD Private Client Wealth's 13F filing for Q2 2026, filed 4 Aug 2026.